Literature DB >> 19349389

Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis?

Ricardo Mingarini Terra1, Jader Joel Machado Junqueira2, Lisete Ribeiro Teixeira3, Francisco Suso Vargas3, Paulo Manuel Pêgo-Fernandes2, Fáabio Biscegli Jatene2.   

Abstract

STUDY
OBJECTIVES: To analyze and compare radiologic lung expansion after talc pleurodesis performed either by videothoracoscopy or chest tube and correlate it with clinical outcome. Secondary end points evaluated were as follows: clinical efficacy; quality of life; safety; and survival.
METHODS: Prospective randomized study that included 60 patients (45 women, 15 men; mean age, 55.2 years) with recurrent malignant pleural effusion between January 2005 and January 2008. They were randomized into the following two groups: video-assisted thoracic surgery (VATS) talc poudrage; and talc slurry (TS) administered through a chest tube. Lung expansion was evaluated through chest CT scans obtained 0, 1, 3 and 6 months after pleurodesis. Complications, drainage time, hospital stay, and quality of life (Medical Outcomes Study 36-item short form and World Health Organization quality-of-life questionnaires) were also analyzed.
RESULTS: There were no significant differences in preprocedure clinical and pathologic variables between groups. The immediate total (ie, > 90%) lung expansion was observed in 27 patients (45%) and was more frequent in the VATS group (60% vs 30%, respectively; p = 0.027). During follow-up, 71% of the patients showed unaltered or improved lung expansion and 9 patients (15%) needed new pleural procedures (VATS group, 5 recurrences; TS group, 4 recurrences; p = 0.999). No differences were found between groups regarding quality of life, complications, drainage time, hospital stay, and survival. Immediate lung expansion did not correlate with radiologic recurrence, clinical recurrence, or complications (p = 0.60, 0.15, and 0.20, respectively).
CONCLUSION: Immediate partial lung expansion was a frequent finding and was more frequent after TS. Nonetheless, no correlation between immediate lung expansion and clinical outcome was found in this study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NTC00789087.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349389     DOI: 10.1378/chest.08-2448

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT.

Authors:  Rahul Bhatnagar; Ramon Luengo-Fernandez; Brennan C Kahan; Najib M Rahman; Robert F Miller; Nick A Maskell
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

Review 2.  Treating Recurrent Pleural Disease: A Review of Indications and Technique for Chemical Pleurodesis for the Interventional Radiologist.

Authors:  Surbhi B Trivedi; Matthew Niemeyer
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

3.  Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions.

Authors:  David E Ost; Jiangong Niu; Hui Zhao; Horiana B Grosu; Sharon H Giordano
Journal:  Chest       Date:  2017-08-31       Impact factor: 9.410

Review 4.  Interventional pulmonologist perspective: treatment of malignant pleural effusion.

Authors:  Andrew J Sweatt; Arthur Sung
Journal:  Curr Treat Options Oncol       Date:  2014-12

Review 5.  Treatment of malignant pleural effusion.

Authors:  Ricardo Mingarini Terra; Alberto Jorge Monteiro Dela Vega
Journal:  J Vis Surg       Date:  2018-05-22

Review 6.  Interventions for the management of malignant pleural effusions: a network meta-analysis.

Authors:  Amelia O Clive; Hayley E Jones; Rahul Bhatnagar; Nancy J Preston; Nick Maskell
Journal:  Cochrane Database Syst Rev       Date:  2016-05-08

7.  Effectiveness and safety of outpatient pleurodesis in patients with recurrent malignant pleural effusion and low performance status.

Authors:  Ricardo Mingarini Terra; Lisete Ribeiro Teixeira; Benoit Jacques Bibas; Paulo Manuel Pego-Fernandes; Francisco Suso Vargas; Fabio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  Evaluation of serial C-reactive protein measurements after surgical treatment of pleural empyema.

Authors:  Israel Lopes Medeiros; Ricardo Mingarini Terra; Esther Mihwa Choi; Paulo Manuel Pego-Fernandes; Fabio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

9.  Does videothoracoscopy improve clinical outcomes when implemented as part of a pleural empyema treatment algorithm?

Authors:  Ricardo Mingarini Terra; Daniel Reis Waisberg; José Luiz Jesus de Almeida; Marcela Santana Devido; Paulo Manuel Pêgo-Fernandes; Fabio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

10.  Wet M1a non-small cell lung cancer: is it possible to predict recurrence of pleural effusion?

Authors:  Fernando Conrado Abrao; Igor Renato Louro Bruno de Abreu; Geisa Garcia Viana; Mariana Campello de Oliveira; Elnara Marcia Negri; Riad Naim Younes
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.